-
Leather jacket worn by Nvidia CEO Jensen Huang auctions for nearly $1 mn
-
Sobers 'stood out' among the greats: West Indies legend Holding
-
Leader Herbert, Burns equal record 62 at British Open, DeChambeau docked two shots
-
DeChambeau's British Open charge hit by two-shot penalty
-
Yankees' Judge improving, but not ready for baseball activities
-
Tech share selloff rolls on, oil prices jump on Mideast clashes
-
None shall pass: Spain's defence ready to thwart Messi in World Cup final
-
Messi eyes second World Cup crown at the scene of his lowest ebb
-
China's Kimi K3 rattles US AI industry
-
Herbert hopes British Open 62 woke Australian kids in the night
-
Herbert takes Open lead, equals Burns' round of 62
-
Norris misses winning, resents intrusions in private life
-
'Great innings ends': Cricket mourns West Indies great Sobers
-
Thousands protest sacking of Ukraine defence minister: AFP
-
Fickle winds whip up huge Spanish wildfire
-
Ex-president Sall back in Senegal for talks with successor
-
US links Taco Bell lettuce to diarrhea-causing parasite outbreak
-
Argentina's Colapinto more nervous about World Cup final than F1 race
-
Strong quake hits southern Mexico, tsunami alert lifted
-
British Museum shows Bayeux Tapestry unfurled after 'titanic' efforts
-
Deschamps set for bittersweet ending to France reign as Zidane waits
-
Ferrari fined but Hamilton and Leclerc escape grid penalty
-
German lawmaker faces criticism for US surrogacy to have a child
-
Tackling Messi 'huge challenge' for Spain: Merino
-
Southern Mexico hit by 7.3 quake, triggering tsunami alert
-
What's behind the Argentina World Cup team's can-do attitude?
-
Germany defender Gosens signs with Schalke
-
Pogacar urges rivals to fight for victory
-
Nigerian court dismisses suit challenging Shell's divestment
-
'Great innings has come to an end' -- cricket legend Sobers dies
-
Ex-president Sall arrives back in Senegal for meeting with successor
-
No tears as Deschamps prepares for final France match
-
Brazil toughens rules on gambling ads as bets explode
-
Antonelli fastest for Mercedes in second practice in Belgium
-
Swiss rider Schmid cramps up but wins Tour de France stage 13
-
US links Taco Bell lettuce to multistate parasite outbreak
-
'Overpriced Dubai skyscraper': Slovaks outraged by ministry's $61-mn HQ
-
Garry Sobers, towering West Indies cricket all-rounder, dies at 89
-
Cubes and lubes: Europe's 'Speedcubers' twist for glory
-
France, Germany plan 'roadmap' to tackle China trade imbalances
-
NFL boss teases Japan among 10 new nations for regular-season games
-
Tech share selloff rolls on, oil prices climb on Mideast clashes
-
Messi eyes glorious farewell as Spain, Argentina clash in World Cup final
-
Swiss rider Schmid wins Tour de France stage 13
-
China landslide kills 8, at least 34 missing: officials
-
Neymar returns to Santos with questions hanging over his future
-
France blocks access to Polymarket
-
Wildfire smoke engulfs millions in US ahead of World Cup final
-
Warholm eyes win in London stadium that kickstarted his career
-
Russia fines anti-war politician as he suffers medical episode
Moderna sues Pfizer, BioNTech over Covid vaccine
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna alleged.
Pfizer and BioNTech said they were aware of the litigation, and each issued statements denying any wrongdoing.
"BioNTech's work is original, and we will vigorously defend against all allegations of patent infringement," the firm said, adding it "respects valid and enforceable intellectual property rights of others."
Pfizer pledged to "vigorously defend against the allegations of the lawsuit."
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are safe and effective.
The lawsuits -- in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on corona viruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
"It is an unfortunate but rather regular occurrence that other companies make allegations that a successful product potentially infringes their intellectual property rights," BioNTech said in a statement.
R.Garcia--AT